OBJECTIVE: Evaluation of the effect of endothelin type A (ET A ) receptor blockade on the course of volume-overload heart failure in rats with angiotensin II-dependent hypertension. METHODS: Ren-2 renin transgenic rats (TGR) were used as a model of hypertension. Heart failure was induced by creating an aorto-caval fistula (ACF). Selective ET A receptor blockade was achieved by atrasentan. For comparison, other rat groups received trandolapril, an angiotensin-converting enzyme inhibitor (ACEi). Animals first underwent ACF creation and 2 weeks later the treatment with atrasentan or trandolapril, alone or combined, was applied; the follow-up period was 20 weeks. RESULTS: Eighteen days after creating ACF, untreated TGR began to die, and none was alive by day 79. Both atrasentan and trandolapril treatment improved the survival rate, ultimately to 56% (18 of 31 animals) and 69% (22 of 32 animals), respectively. Combined ACEi and ET A receptor blockade improved the final survival rate to 52% (17 of 33 animals). The effects of the three treatment regimens on the survival rate did not significantly differ. All three treatment regimens suppressed the development of cardiac hypertrophy and lung congestion, decreased left ventricle (LV) end-diastolic volume and LV end-diastolic pressure, and improved LV systolic contractility in ACF TGR as compared with their untreated counterparts. CONCLUSION: The treatment with ET A receptor antagonist delays the onset of decompensation of volume-overload heart failure and improves the survival rate in hypertensive TGR with ACF-induced heart failure. However, the addition of ET A receptor blockade did not enhance the beneficial effects beyond those obtained with standard treatment with ACEi alone.

Center for Experimental Medicine Institute for Clinical and Experimental Medicine

Department of Cardiology University Hospital Motol and 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Internal Medicine 1 Cardiology University Hospital Olomouc and Palacký University Olomouc

Department of Pathophysiology 2nd Faculty of Medicine Charles University

Department of Renal and Body Fluid Physiology Mossakowski Medical Research Institute Polish Academy of Science Warsaw Poland

Institute of Physiology of the Czech Academy of Sciences Prague Czech Republic

Zobrazit více v PubMed

Bulluck H, Yellon DM, Hausenloy DJ. Reducing myocardial infarct size: challenges and future opportunities. PubMed PMC

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. PubMed

Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats A. Global burden of heart failure: A comprehensive and updated review of epidemiology. PubMed

Kassi M, Hannawi B, Trachtenberg B. Recent advances in heart failure. PubMed

Rangawwami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. PubMed

McDonagh TS, Metra M, Adamo A, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. PubMed

Murphy SP, Ibrahim NE, Januzzi J, Jr. Heart failure with reduced ejection fraction. PubMed

The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). PubMed

Yusuf S, Pitt B, Davis CE, Hood WB, Jr, Cohn JN. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. PubMed

Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure. PubMed

Pfeffer MA. Heart failure and hypertension: importance of prevention. PubMed

Pinho-Gomes AC, Azevedo L, Bidel Z, Nazarzadeh M, Canoy D, Copland E, et al. Effects of blood pressure-lowering drugs in heart failure: a systemic review and meta-analysis of randomized controlled trials. PubMed

Ryan TD, Rothstein EC, Aban I, Tallaj JA, Hussain A, Lucchesi PA, et al. Left ventricular eccentric remodellin and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload. PubMed

Plante E, Lachance D, Beaudoin J, Champetier S, Roussel E, Arsenault M, et al. Comparative study of vasodilators in an animal mode of chronic volume overload caused by severe aortic regurgitation. PubMed

Červenka L, Melenovský V, Husková Z, Škaroupková P, Nishiyama A, Sadowski J. Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula. PubMed

Ciccarelli M, Dawson D, Falcao-Pires I, Giacca M, Hamdani N, Heymans S, et al. Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function. PubMed PMC

Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. PubMed

Dube P, Weber KT. Congestive heart failure: pathophysiologic consequences of neurohormonal activation and the potential for recovery: Part I. PubMed

Mann DL, Felker GM. Mechanisms and models in heart failure. PubMed PMC

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. PubMed

Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollkock JS, et al. Endothelin. PubMed PMC

Dhaun NJ, Webb DJ. Endothelins in cardiovascular biology and therapeutics. PubMed

Barton M, Yanagisawa M. Endothelin: 30 years from discovery to therapy. PubMed

Miyauchi T, Sakai S. Endothelin and the heart in health and diseases. PubMed

Eroglu E, Kocyigit I, Linholm B. The endothelin system as target for therapeutic interventions in cardiovascular and renal disease. PubMed

Kobayashi T, Miyauchi T, Sakai S, Kobayashi M, Yamaguchi I, Goto K, et al. Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing heart. PubMed

Motte S, van Beneden R, Mottet J, Rondelet B, Mathieu M, Havaux X, et al. Early activation of cardia and renal endothelin systems in experimental heart failure. PubMed

Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. PubMed

Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. PubMed

Mulder P, Boujedainin H, Richard V, Henry JP, Renet S, Munter K, et al. Long-term survival and hemodynamics after endothelin-A receptor antagonism and angiotensin-converting enzyme inhibition in rats with chronic heart failure. Monotherapy versus combination therapy. PubMed

Lee DS, Nguyen QT, Lapointe N, Austin F, Ohlsson A, Tu JV, et al. Meta-analysis of the effects of endothelin receptor blockade on survival in experimental heart failure. PubMed

Xia QG, Reinecke A, Dorenkamp M, Daemen MJ, Simon R, Unger T. Effects of endothelin ET PubMed

Luscher TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, et al. Hemodynamic and neurohormonal effects of selective endothelin A (ET PubMed

Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzaou K, et al. Long-term effects of darusentan on left-ventricular remodeling and clinical outcomes in EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomized, double-blind, placebo-controlled trial. PubMed

Mann JFE, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, et al. Avosentan for over diabetic nephropathy. PubMed PMC

Packer M, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, et al. Long-term effect on endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure. Primary results of the ENABLE trials. PubMed

Gottlieb SS, Theory fact. Revisiting association and causation. PubMed

Čertíková Chábová V, Vernerová Z, Kujal P, Husková Z, Škaroupková P, Tesař V, et al. Addition of ETA receptor blockade increases renoprotection provided by renin–angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats. PubMed

Sedláková L, Čertíková Chábová V, Doleželová Š, Škaroupková P, Kopkan L, Husková Z, et al. Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. PubMed

Vaněčková I, Hojná S, Vernerová Z, Kadlecová M, Rauchová H, Kompanowska-Jezierska E, et al. Renoprotection provided by additional diuretic treatment in partially nephrectomized Ren-2 transgenic rats subjected to the combined RAS and ETA blockade. PubMed PMC

Heerspinkg HJ, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, et al. Atresantan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomized, placebo-controlled trial. PubMed

Brower GL, Levick SP, Janicki JS. Differential effects of prevention and reversal treatment with Lisinopril on left ventricular remodeling in a rat model of heart failure. PubMed PMC

Oliver-Dussault C, Ascah A, Marcil M, Matas J, Picard S, Pibarot P, et al. Early predictors of cardiac decompensation in experimental volume overload. PubMed

Abassi Z, Goltsmna I, Karram T, Winaver J, Horrman A. Aortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy. PubMed PMC

Honetschlagerová Z, Gawrys O, Jíchová Š, Škaroupková P, Kikerlová S, Vaňourková Z, et al. Renal sympathetic denervation attenuates congestive heart failure in angiotensin II-dependent hypertension: studies with Ren-2 transgenic hypertensive rats with aorto-caval fistula. PubMed

Honetschlagerová Z, Škaroupková P, Kikerlová S, Husková Z, Maxová H, Melenovský V, et al. Effects of renal sympathetic denervation on the course of congestive heart failure combined with chronic kidney disease: insight from studies with fawn-hooded hypertensive rats with volume overload induced using aorto-caval fistula. PubMed

Kala P, Miklovič M, Jíchová Š, Škaroupková P, Vaňourková Z, Maxová H, et al. Effects of Epoxyeicosatrienoic acid-enhancing therapy on the course of congestive heart failure in angiotensin II-dependent rat hypertension: from mRNA analysis towards functional in vivo evaluation. PubMed PMC

Houser SR, Margulies KB, Murphy AM, Spinale FG, Francis GS, Prabhu SD. Animal models of heart failure: a scientific statement from the American Heart Association. PubMed

Riehle C, Bauersachs J. Small animals models of heart failure. PubMed PMC

Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harboring the mouse Ren-2 gene. PubMed

Husková Z, Kramer HJ, Vaňourková Z, Červenka L. Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. PubMed

Sobieraj P, Nisson PM, Kahan T. Heart failure events in a clinical trial on arterial hypertension: new insights into the SPRINT trial. PubMed

Aimo A, Vergaro G, Passion C, Clerico A. Evaluation of pathophysiological relationship between renin-angiotensin systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. PubMed

Antoine S, Vaidya G, Imam H, Villarreal D. Pathophysiologic mechanisms in heart failure: role of the sympathetic nervous system. PubMed

Floras JS. The 2021 Carl Ludwig Lecture. Unsympathetic autonomic regulation in heart failure: patients-inspired insights. PubMed

Grassi G, Mancia G, Esler M. Central and peripheral sympathetic activation in heart failure. PubMed

Cohen J. Cohen J. Some issue in power analysis.

Wang X, Ren B, Liu S, Sentex E, Tappia PS, Dhalla NS. Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. PubMed

Kratky V, Vanourkova Z, Sykora M, Szeiffova Bacova B, Hruskova Z, Kikerlova S, et al. AT1 receptor blocker, but not an ACE inhibitor, prevents kidneys from hypoperfusion during congestive heart failure in normotensive and hypertensive rats. PubMed PMC

Pacher P, Nagayama T, Mukhopadhyay P, Bátkai S, Kass DA. Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats. PubMed PMC

Kala P, Bartušková H, Pit’ha J, Vaňourková Z, Kikerlová S, Jíchová Š, et al. Deleterious effects of hyperactivity of the renin-angiotensin system and hypertension on the course of chemotherapy-induced heart failure after doxorubicin administration: a study in Ren-2 transgenic rats. PubMed PMC

Havlenova T, Skaroupkova P, Miklovic M, Behounek M, Chmel M, Jarkovaska D, et al. Right versus left ventricular remodeling in heart failure due to chronic volume overload. PubMed PMC

Opočenský M, Kramer HJ, Bäcker A, Vernerová Z, Eis V, Červenka L, et al. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. PubMed

Husková Z, Kopkan L, Červenková L, Doleželová Š, Vaňourková Z, Škaroupková P, et al. Intrarenal alterations of the angiotensin-converting type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats. PubMed

Kohno M, Horio T, Ikeda M, Yokowa K, Fukui T, Yasunari K, et al. Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. PubMed

Barton M, Shaw S, d’Uscio LV, Moreau P, Luscher T. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin-converting enzyme activity in vivo: role of ET PubMed

Kawaguchi H, Sawa H, Yasuda H. Effects of endothelin on angiotensin converting enzyme activity in cultured pulmonary artery endothelial cells. PubMed

Stehouwer CDA, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. PubMed

Currie G, Delles C. Proteinuria and its relation to cardiovascular disease. PubMed PMC

Liang W, Liu Q, Wang Q-y, Yu H, Yu J. Albuminuria and dipstick proteinuria for predicting mortality in heart failure: a systematic review and meta-analyses. PubMed PMC

Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin–angiotensin–aldosterone system. PubMed

Komers R, Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. PubMed PMC

Emori T, Hirata Y, Ohta K, Kanno K, Eguchi S, Imai T, et al. Cellular mechanisms of endothelin-1 release by angiotensin and vasopressin. PubMed

Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. PubMed

Pilz PM, Ward JE, Chang WT, Kiss A, Bateh E, Jha A, et al. Large and small animal models of heart failure with reduced ejection fraction. PubMed

Vacková Š, Kikerlová S, Melenovský V, Kolář F, Imig JD, Kompanowska-Jezierska E, et al. Altered renal vascular responsiveness to vasoactive agents in rats with angiotensin II-dependent hypertension and congestive heart failure. PubMed PMC

Santos RAS, Sampaion WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, et al. The ACE2/angiotensin-(1-7)/Mas axis of the renin–angiotensin system: focus on the angiotensin-(1-7). PubMed PMC

Bürgelová M, Kramer HJ, Teplan V, Thumová M, Červenka L. Effects of angiotensin-(1-7) blockade on renal function in rats with enhanced intrarenal ANG II activity. PubMed

Wang K, Basu R, Poglitsch M, Bakal JA, Stat P, Oudit GY. Elevated angiotensin 1-7/angiotensin II ratio predicts favorable outcomes in patients with heart failure. PubMed

The role of ventricular remodeling in the early decompensation of cardiorenal syndrome: Insight from studies with Ren-2 transgenic hypertensive rats subjected to volume overload induced using aorto-caval fistula

Effects of renal denervation on the course of cardiorenal syndrome: insight from studies with fawn-hooded hypertensive rats

Altered Balance between Vasoconstrictor and Vasodilator Systems in Experimental Hypertension

Characterization of a new model of chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome in Ren-2 transgenic rats

Sex-Linked Differences in Cardiac Atrophy After Mechanical Unloading Induced by Heterotopic Heart Transplantation

The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula

The treatment with trandolapril and losartan attenuates pressure and volume overload alternations of cardiac connexin-43 and extracellular matrix in Ren-2 transgenic rats

Impaired renal autoregulation and pressure-natriuresis: any role in the development of heart failure in normotensive and angiotensin II-dependent hypertensive rats?

Inappropriate activation of the renin-angiotensin system improves cardiac tolerance to ischemia/reperfusion injury in rats with late angiotensin II-dependent hypertension